tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Dynavax sees FY23 HEPLISAV-B net product revenue $165M-$185M

Sees FY23 research and development expenses $55M-$70M; and selling, general and administrative expenses $135M- $155M.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly

See the top stocks recommended by analysts >>

Read More on DVAX:

Disclaimer & DisclosureReport an Issue

1